Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Frontline ALK+ NSCLC management

Tom Newsom-Davis • 30 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, discusses the management of ALK+ non-small cell lung cancer (NSCLC) with a focus on brain metastases. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Tom Newsom-Davis

0:47
Novel insights from BTOG 2023
Tom Newsom-Davis • 3 May 2023
1:53
The role of NICE in the UK for lung cancer
Tom Newsom-Davis • 27 Apr 2023
1:57
BTOG 2021 highlights: immunotherapy for mesothelioma and cardiac toxicity updates
Tom Newsom-Davis • 23 Apr 2021
2:39
COVID-19 and the future of lung cancer treatment in the UK
Tom Newsom-Davis • 23 Apr 2021

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals